Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 23.03.2026 1 Am J Pathol 3 Ann Surg Oncol 2 Ann Thorac Surg 1 Arch Bronconeumol 3 BMC Cancer 1 Br J Cancer 2 Cancer 2 Cancer Lett 2 Chest 1 Clin Cancer Res 2 Clin Exp Metastasis 10 Clin Lung Cancer 1 Eur J Cardiothorac Surg 1 Eur Respir J 3 Int J Cancer 6 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Immunol 1 J Natl Cancer Inst 2 J Thorac Oncol 1 JAMA Oncol 1 Lancet 1 Lancet Oncol 5 Lung Cancer 1 Mol Cancer Ther 1 Oncogene 4 PLoS One 1 Proc Natl Acad Sci U S A 2 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. BRECHENMACHER C, Kezlarian B, Weirich G, Botelho S, et al
   Machine Learning Predicts Adequacy of Rapid Onsite Evaluation in Fine Needle Aspirations in Lung Cancer Cytology.
   Am J Pathol. 2026 Mar 18:S0002-9440(26)00067.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. LIU Z, Guo H
   ASO Author Reflections: Unmasking the Silent Threat: Myocardial Injury After Lung Cancer Surgery and Its Link to Major Adverse Cardiovascular Events.
   Ann Surg Oncol. 2026 Mar 18. doi: 10.1245/s10434-026-19515.
   PubMed        
   
   
3. LIU C, Liao Y, Wang D, Yang J, et al
   ASO Visual Abstract: Machine Learning for Classification in Lung Cancer Using Routine Clinical and Laboratory Data.
   Ann Surg Oncol. 2026 Mar 17. doi: 10.1245/s10434-026-19444.
   PubMed        
   
   
4. SINGH A, Xie Y, McAllister MA, Mazzola E, et al
   Multifactorial Impact of Age, Race, and Female Sex on Management of Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2026 Mar 14. doi: 10.1245/s10434-026-19411.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. VALDERRAMA A, Williams KM, Soe A, Velotta JB, et al
   Defining Surgical Timeliness as a Quality Metric in Early-Stage Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2026 Mar 14:S0003-4975(26)00226.
   PubMed        
   
   
6. RUSCH VW
   Optimizing lung cancer screening.
   Ann Thorac Surg. 2026 Mar 12:S0003-4975(26)00211.
   PubMed        
   
   

   
   Arch Bronconeumol

7. ZENG B, Huang X, Lai B
   Navigating Diagnostic and Therapeutic Challenges in Rare SMARCA4-deficient Lung Cancer: Achieving Partial Response Through Regimen Change.
   Arch Bronconeumol. 2026 Feb 27:S0300-2896(26)00083.
   PubMed        
   
   

   
   BMC Cancer

8. LI J, Tai Y, Pan B, Xiang L, et al
   Efficacy and prognostic factors of stereotactic radiosurgery versus whole-brain radiotherapy for brain metastases in small cell lung cancer: a systematic review and meta-analysis.
   BMC Cancer. 2026 Mar 18. doi: 10.1186/s12885-026-15871.
   PubMed        
   
   
9. LEE KC, Shin H, Ohn J, Park JH, et al
   Diagnostic accuracy of an AI-based pathologic response assessment in locally advanced non-small cell lung cancer after neoadjuvant chemo-immunotherapy.
   BMC Cancer. 2026 Mar 20. doi: 10.1186/s12885-026-15885.
   PubMed        
   
   
10. JAYAMANNE D, Suri T, Bergamin S, Metz G, et al
    Outcome analysis and associations with Charlson comorbidity index in the early-stage lung cancer patients treated with stereotactic radiotherapy.
    BMC Cancer. 2026 Mar 20. doi: 10.1186/s12885-026-15814.
    PubMed        
    
    

    
    Br J Cancer

11. HUANG Q, Zhao J, Zhang Y, Zhou Y, et al
    eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia.
    Br J Cancer. 2026;134:996-1005.
    PubMed         Abstract available
    
    

    
    Cancer

12. SONG C, Zhao X, Li S, Guo X, et al
    Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial.
    Cancer. 2026;132:e70351.
    PubMed         Abstract available
    
    
13. BORYSOWSKI J, Klosowska D, Harhala M, Knetki-Wroblewska M, et al
    Eligibility criteria in phase 3 randomized controlled trials in metastatic non-small cell lung cancer.
    Cancer. 2026;132:e70361.
    PubMed         Abstract available
    
    

    
    Cancer Lett

14. FABRIZIO FP, Pegreffi F, Leonardi R, Mazza M, et al
    Can Macrophages Predict Response to Neoadjuvant Therapy in Lung Cancer? A Lesson from Breast Cancer.
    Cancer Lett. 2026 Mar 17:218438. doi: 10.1016/j.canlet.2026.218438.
    PubMed        
    
    
15. WU H, Zhang J, Yu Y, Wang W, et al
    BRIP1-mediated RINT1 acetylation and NF-kappaB activation promote DNA repair and immunosuppressive microenvironment in lung adenocarcinoma.
    Cancer Lett. 2026;645:218357.
    PubMed         Abstract available
    
    

    
    Chest

16. LONG KJ, Ward R, Kazerooni E, Pinsky P, et al
    New and growing nodules are strongly associated with malignancy in follow-up screens for lung cancer: a cohort study.
    Chest. 2026 Mar 16:S0012-3692(26)00305-3. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    
17. ARO RP, Lam S, Warkentin MT, Liu G, et al
    Integrating deep learning of low-dose computed tomography with clinical data for lung cancer risk prediction.
    Chest. 2026 Mar 13:S0012-3692(26)00296-5. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

18. HUANG B, Zhao J, Zhu J, Wang X, et al
    Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer.
    Clin Cancer Res. 2026 Mar 18. doi: 10.1158/1078-0432.CCR-25-4153.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

19. ZHANG Y, Li X, Liu S, Xue Q, et al
    LINC01996 suppresses non-small cell lung cancer proliferation and metastasis by orchestrating the miR-12115/CNRIP1/Ras signaling axis.
    Clin Exp Metastasis. 2026;43:18.
    PubMed         Abstract available
    
    
20. CAIVANO D, Pezzulla D, Bonome P, Palmeri F, et al
    Predictive factors of response in lung metastases treated by sbrt from colon rectal cancer.
    Clin Exp Metastasis. 2026;43:19.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

21. TAKAGAWA T, Takahashi K, Orimoto Y, Morisaki Y, et al
    Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
    Clin Lung Cancer. 2026;27:75-79.
    PubMed         Abstract available
    
    
22. YEUNG AML, Chow JCH
    Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review.
    Clin Lung Cancer. 2026;27:85-97.
    PubMed         Abstract available
    
    
23. PATEL JD, Meng J, Jimenez-Moreno AC, Coerts F, et al
    Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study.
    Clin Lung Cancer. 2026;27:1-11.
    PubMed         Abstract available
    
    
24. DETTERBECK F, Rami-Porta R
    Striving for an Enhanced Tumor Classification System: Reflections on Cancer, Prognosis, Human Nature and Reality.
    Clin Lung Cancer. 2026;27:237-241.
    PubMed         Abstract available
    
    
25. KWON H, Viray H, Gaudet RE, VanderLaan PA, et al
    Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.
    Clin Lung Cancer. 2026;27:12-16.
    PubMed        
    
    
26. CITARELLA F, Mingo EC, Fiorenti M, Russano M, et al
    Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review.
    Clin Lung Cancer. 2026;27:59-68.
    PubMed         Abstract available
    
    
27. LIU Z, Peng Z, Cao J, Huang Z, et al
    Effect of adjuvant EGFR-TKI therapy on the prognosis of pathological stage I invasive lung adenocarcinoma with sensitive EGFR mutations.
    Clin Lung Cancer. 2026;27:177-188.
    PubMed         Abstract available
    
    
28. LI BT, Gandhi L, Ravichandran V, Besse B, et al
    Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.
    Clin Lung Cancer. 2026;27:214-226.
    PubMed         Abstract available
    
    
29. BRUNI A, Franceschini D, Marini B, Vagge S, et al
    Clinical Outcomes and Predictive Factors in NSCLC after Surgery: Findings from the RAC-TAC Study.
    Clin Lung Cancer. 2026;27:242-248.
    PubMed         Abstract available
    
    
30. SHI J, Xu K, Liu X, Shi M, et al
    Anaplastic Lymphoma Kinase Rearrangement and Tumor Spread Through Air Spaces Is Associated with Worse Clinical Outcomes for Resected Stage IA Lung Adenocarcinoma.
    Clin Lung Cancer. 2026;27:151-160.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

31. GEENEN L, Verkoulen KCHA, Laven IEWG, Daemen JHT, et al
    A Network Meta-Analysis of Drainage Systems and Suction Strategies After Lung Cancer Surgery.
    Eur J Cardiothorac Surg. 2026 Mar 14:ezag127. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Eur Respir J

32. KIM H, Jo E, Kim J, Ho Yoon S, et al
    Associations between High-Density Lipoprotein Cholesterol and Interstitial Lung Abnormalities in the Korean National Lung Cancer Screening.
    Eur Respir J. 2026 Mar 19:2501878. doi: 10.1183/13993003.01878-2025.
    PubMed         Abstract available
    
    

    
    Int J Cancer

33. PARK S, Kang D, Lee J, Jung HA, et al
    Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single-center experience.
    Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70449.
    PubMed         Abstract available
    
    
34. JIN D, Zhong L, Chen L
    Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances.
    Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70419.
    PubMed         Abstract available
    
    
35. TANG W, Hou X, Li L, Zhao H, et al
    Coronavirus disease 2019 infection reduces EGFR-TKI efficacy in non-small cell lung carcinoma: Real-world evidence from a multicenter propensity-matched cohort.
    Int J Cancer. 2026 Mar 20. doi: 10.1002/ijc.70444.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

36. SALUNKHE R, Palma DA, Warner A, Bahig H, et al
    Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial.
    Int J Radiat Oncol Biol Phys. 2026;124:1290-1297.
    PubMed         Abstract available
    
    
37. ABI JAOUDE J, Cui S, Fu J, Worth JE, et al
    Local Control in Thoracic Stereotactic Ablative Radiation Therapy: Analysis of Motion Management and Single-Fraction Dosimetry From the iSABR Trial.
    Int J Radiat Oncol Biol Phys. 2026;124:1309-1317.
    PubMed         Abstract available
    
    
38. FUCHS F, Herrera R, Kotecha R, Rubens M, et al
    Multi-institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy.
    Int J Radiat Oncol Biol Phys. 2026;124:1421-1430.
    PubMed         Abstract available
    
    
39. KARLSSON K, Rancati T, Lindback E, Lindberg S, et al
    Dose-Volume Predictors of Fatal Bronchopulmonary Bleeding After Stereotactic Body Radiation Therapy of Centrally Located Lung Tumors: An Analysis of the Expanded HILUS Cohort.
    Int J Radiat Oncol Biol Phys. 2026;124:1298-1308.
    PubMed         Abstract available
    
    
40. SINGH AK, Farrugia MK, Stephans KL, Bogart JA, et al
    Long-term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2026 Mar 13:S0360-3016(26)00487.
    PubMed         Abstract available
    
    
41. ZRAFI WS, Albarran-Artahona V, Dall'Olio FG, Ghigna MR, et al
    Tumor purity as a prognostic and predictive biomarker of postoperative radiotherapy outcomes in stage IIIA-N2 non-small-cell lung cancer: a transcriptomic analysis from the Lung ART trial.
    Int J Radiat Oncol Biol Phys. 2026 Mar 13:S0360-3016(26)00491.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

42. SCHERPEREEL A, Baas P, Nowak AK, Tsao AS, et al
    Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
    J Clin Oncol. 2026;44:742-749.
    PubMed         Abstract available
    
    

    
    J Immunol

43. CANNON A, Zhang J, Ropa J, Pajulas A, et al
    Macrophage-intrinsic and IL-9-dependent arginine metabolism promotes lung tumor growth.
    J Immunol. 2026;215:vkag026.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

44. NALINI M, O'Brien KM, Calafat AM, Wang L, et al
    Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis.
    J Natl Cancer Inst. 2026 Mar 18:djag078. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

45. JUANG YR, Zhao Q, Pyng L, Seow WJ, et al
    REMOVED: PP01.04: Lung Cancer Risk Factors in Singapore: A Systematic Review and Meta-analysis With Comparative Insights From Across Asia.
    J Thorac Oncol. 2026;21.
    PubMed         Abstract available
    
    
46. YANG SR, Tjota MY, Goren E, Giroux DJ, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9(th) Edition Staging Database.
    J Thorac Oncol. 2026 Mar 13:103681. doi: 10.1016/j.jtho.2026.103681.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

47. LI R, Wang P, Zhang H, Zeng Q, et al
    Lymph Node Dissection Guideline Adherence and Survival in Patients With T1N0M0 Lung Adenocarcinoma.
    JAMA Oncol. 2026;12:266-274.
    PubMed         Abstract available
    
    

    
    Lancet

48. GUIMARAES RA
    National lung cancer screening programme in Brazil: an urgent need.
    Lancet. 2026;407:1055.
    PubMed        
    
    

    
    Lancet Oncol

49. ZHONG H, Wang J, Yang R, Luo Y, et al
    Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026 Mar 10:S1470-2045(26)00049.
    PubMed         Abstract available
    
    

    
    Lung Cancer

50. ARAUJO BJ, Visani F, Paes RD, Negrete CL, et al
    Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort.
    Lung Cancer. 2026;215:109370.
    PubMed         Abstract available
    
    
51. WANG J, Zhong Y, Chen B, Xu Y, et al
    Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study.
    Lung Cancer. 2026;215:109369.
    PubMed         Abstract available
    
    
52. LV D, Zhu R, Wu G, Zhang Y, et al
    Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1.
    Lung Cancer. 2026;215:109371.
    PubMed         Abstract available
    
    
53. LIN SH, Kahangire DA, Nagar SP, Ahn MJ, et al
    EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.
    Lung Cancer. 2026;215:109348.
    PubMed         Abstract available
    
    
54. NAIDOO J, Peters S, Runglodvatana Y, Li JY, et al
    Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.
    Lung Cancer. 2026;215:109316.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

55. DUTTA CHOWDHURY D, Imada EL, Connis N, Chang J, et al
    TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer.
    Mol Cancer Ther. 2026 Mar 16. doi: 10.1158/1535-7163.MCT-25-0529.
    PubMed         Abstract available
    
    

    
    Oncogene

56. WILLIAMS AE, Hoffmann EJ, Inman DR, Gari MK, et al
    Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasis.
    Oncogene. 2026 Feb 28. doi: 10.1038/s41388-026-03718.
    PubMed         Abstract available
    
    

    
    PLoS One

57. NIINO M, Tomizuka T, Nishina Y, Ichinose Y, et al
    A nationwide survey on the prevalence of asbestos-related lung cancer in Japan.
    PLoS One. 2026;21:e0313468.
    PubMed         Abstract available
    
    
58. YASMIN MF, Hosen MF, Basar MA, Rahman A, et al
    Gene expression and metadata based identification of key genes for lung cancer, COPD, and IPF using machine learning and statistical models.
    PLoS One. 2026;21:e0344666.
    PubMed         Abstract available
    
    
59. JADIDI M, Svalkvist A, Bath M, Nyren S, et al
    Can the current radiation dose, in chest tomosynthesis, be reduced with retained image quality? A study in the context of lung cancer screening programs.
    PLoS One. 2026;21:e0343760.
    PubMed         Abstract available
    
    
60. CHEN H, Chen X, Lin W, Chen Q, et al
    Elucidating the mechanistic association of xylene inducing non-small cell lung cancer through network toxicology and molecular docking analysis.
    PLoS One. 2026;21:e0341548.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

61. ABT ER, Wang L, Varuzhanyan G, Freeland J, et al
    Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade.
    Proc Natl Acad Sci U S A. 2026;123:e2532814123.
    PubMed         Abstract available
    
    

    
    Thorax

62. MURRAY RL, Baldwin D, Brain K, Britton J, et al
    Randomised trial of delivering co-located, personalised stop-smoking support within lung cancer screening: the YESS study.
    Thorax. 2026 Mar 13:thorax-2025-224217. doi: 10.1136/thorax-2025-224217.
    PubMed         Abstract available
    
    
63. JOHNSON J, Johnson SR
    Prevalence and assessment of exercise-induced desaturation in lymphangioleiomyomatosis.
    Thorax. 2026;81:389-391.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum